Update on fda priority review of dupixent® (dupilumab) for the treatment of copd patients with type 2 inflammation

Tarrytown, n.y. and paris, may 31, 2024 (globe newswire) -- regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced the u.s. food and drug administration (fda) has extended by three months the target action date of its priority review of the supplemental biologics license application (sbla) for dupixent® (dupilumab) as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (copd). the revised target action date is september 27, 2024. the fda did not raise any concerns regarding the approvability of dupixent for this indication.
REGN Ratings Summary
REGN Quant Ranking